This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.
Study Type
OBSERVATIONAL
Enrollment
1,007
Distribution of patients receiving unique treatment regimen/sequence of treatment regimens
Time frame: Up to 8 years
Progression-free survival (PFS)
Time frame: Up to 8 years
Overall survival (OS)
Time frame: Up to 8 years
Post-progression survival (PPS)
Time frame: Up to 8 years
Time-to-treatment failure (TTF)
Time frame: Up to 8 years
Response rate (RR)
Time frame: Up to 8 years
Safety: Incidence of adverse events
Time frame: Up to 8 years
Patient-reported outcome assessment (PRO)
Time frame: Up to 8 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
St. Vincent'S Hospital; Birmingham Hematology Oncology Associates, Llc
Birmingham, Alabama, United States
University of South Alabama; Mitchell Cancer Institute
Mobile, Alabama, United States
Arizona Oncology Associates, PC - NAHOA
Sedona, Arizona, United States
Arizona Oncology
Tucson, Arizona, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
NEA Baptist Clinic
Jonesboro, Arkansas, United States
Hematology Oncology Services of Arkansas
Little Rock, Arkansas, United States
Highlands Oncology Group
Rogers, Arkansas, United States
East Valley Hem/Onc Med Group; Metropolitan Hem Onc.
Burbank, California, United States
South Bay Oncology Hematology Partners
Campbell, California, United States
...and 132 more locations